Emiliano Biasini is an associate professor in the Department CIBIO, leading research on brain disorders. He co-founded Sibylla Biotech, where he serves as a board director. His work on the Pharmacological Protein Inactivation by Folding Intermediate Targeting (PPI-FIT) technology has driven advancements in drug discovery. He trained in pharmacology, biochemistry, and molecular biology at Washington University in St. Louis, the Mario Negri Institute in Milan, and Boston University. He holds over 60 publications, 4 patents, and multiple research grants. His work has been showcased at international scientific conferences and featured in public media.